Loading...
Docoh

Inhibikase Therapeutics (IKT)

Employees
Data from SEC filings
Employee count
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The 2021 Annual Meeting of Stockholders (“Annual Meeting”) of Inhibikase Therapeutics, Inc. (the “Company”) was held on June 25, 2021. The following proposals were approved at the Annual Meeting by the votes indicated:
Proposal One: To elect one director to the board of directors of the Company to serve as the Class I director, to serve until the Company’s 2024 annual meeting of stockholders or until his respective successor is duly elected and qualified. The nominee for election was Milton H. Werner, Ph.D.
The following nominee was elected by the votes indicated to serve as the Class I director, to serve until the Company’s 2024 annual meeting of stockholders or until his respective successor is duly elected and qualified:

NameTotal Votes
for Director
Total Votes
Withheld from
Director
Total Broker
Non-Votes
Milton H. Werner, Ph.D.6,172,09025,573720,818
Proposal Two: To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.

Total Votes
For6,892,719
Against3,591
Abstain22,171
Broker Non-Votes0

-2-